Male Breast Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Male Breast Cancer
Breast cancer in men is treated the same as breast cancer in women. (See the PDQ summary on Breast Cancer Treatment for more information.)Initial SurgeryTreatment for men diagnosed with breast cancer is usually modified radical mastectomy. Breast-conserving surgery with lumpectomy may be used for some men.Adjuvant TherapyTherapy given after an operation when cancer cells can no longer be seen is called adjuvant therapy. Even if the doctor removes all the cancer that can be seen at the time of the operation, the patient may be given radiation therapy, chemotherapy, hormone therapy, and/or targeted therapy after surgery, to try to kill any cancer cells that may be left.Node-negative: For men whose cancer is node-negative (cancer has not spread to the lymph nodes), adjuvant therapy should be considered on the same basis as for a woman with breast cancer because there is no evidence that response to therapy is different for men and women.Node-positive: For men whose cancer is
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Appendix of Randomized Controlled Trials
Health Insurance Plan, United States 1963 [1,2]Age at entry: 40 to 64 years.Randomization: Individual, but with significant imbalances in the distribution of women between assigned arms, as evidenced by menopausal status (P < .0001) and education (P = .05). Sample size: 30,000 to 31,092 in study group and 30,565 to 30,765 in control group. Consistency of reports: Variation in sample size reports. Intervention: Annual two-view mammography (MMG) and CBE for 3 years. Control: Usual care. Compliance: Nonattenders to first screening (35% of the screened population) were not reinvited.Contamination: Screening MMG was not available outside the trial, but frequency of CBE performance among control women is unknown.Cause of death attribution: Women who died of breast cancer that had been diagnosed before entry into the study were excluded from the comparison between the screening and control groups. However, these exclusions were determined differently
Breast Cancer Treatment and Pregnancy (PDQ®): Treatment - Patient Information [NCI] - Recurrent Breast Cancer
Recurrent breast cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the breast, in the chest wall, or in other parts of the body.
Breast Cancer Treatment and Pregnancy (PDQ®): Treatment - Patient Information [NCI] - General Information about Breast Cancer and Pregnancy
Breast cancer is a disease in which malignant (cancer) cells form in the tissues of the breast. The breast is made up of lobes and ducts. Each breast has 15 to 20 sections called lobes,which have many smaller sections called lobules. The lobes and lobules are connected by thin tubes called ducts. Anatomy of the breast,showing lymph nodes and lymph vessels. Each breast also contains blood ...
Breast Cancer Treatment and Pregnancy (PDQ®): Treatment - Patient Information [NCI] - Stages of Breast Cancer
After breast cancer has been diagnosed, tests are done to find out if cancer cells have spread within the breast or to other parts of the body. The process used to find out if the cancer has spread within the breast or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment.Methods used to stage breast cancer can be changed to make them safer for the fetus. Standard methods for giving imaging scans can be adjusted so that the fetus is exposed to less radiation. The following tests and procedures may be used in the staging process:Sentinel lymph node biopsy: The removal of the sentinel lymph node during surgery. The sentinel lymph node is the first lymph node to receive lymphatic drainage from a tumor. It is the first lymph node the cancer is likely to spread to from the tumor. A radioactive substance and/or blue dye is injected near the tumor. The
Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I, II, IIIA, and Operable IIIC Breast Cancer
Primary TherapyLocal-regional treatmentStage I, II, IIIA, and operable IIIC breast cancer often requires a multimodality approach to treatment. Irrespective of the eventual procedure selected, the diagnostic biopsy and surgical procedure that will be used as primary treatment should be performed as two separate procedures. In many cases, the diagnosis of breast carcinoma is made by core needle biopsy. After the presence of a malignancy is confirmed, treatment options should be discussed with the patient before a therapeutic procedure is selected. Estrogen-receptor (ER) and progesterone-receptor (PR) protein status and human epidermal growth factor receptor 2 (HER2/neu) status should be determined for the primary
Breast Cancer Treatment and Pregnancy (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Breast Cancer Treatment and Pregnancy
Procedures used for determining the stage of breast cancer should be modified for pregnant women to avoid radiation exposure to the fetus. Nuclear scans cause fetal radiation exposure. If such scans are essential for evaluation, hydration and Foley catheter drainage of the bladder can be used to prevent retention of radioactivity. Timing of the exposure to radiation relative to the gestational age of the fetus may be more critical than the actual dose of radiation delivered. Radiation exposure during the first trimester (>0.1 Gy) may lead to congenital malformations, mental retardation, and increased relative risk of carcinogenesis. Doses greater than 1 Gy may produce congenital abnormalities. Doses of 0.1 Gy may result in fewer defects. Chest x-rays with abdominal shielding are considered safe, but as with all radiologic procedures, they should be used only when essential for making treatment decisions.[1,3] A chest x-ray delivers 0.00008 Gy.For the diagnosis of bone
Breast Cancer Treatment and Pregnancy (PDQ®): Treatment - Health Professional Information [NCI] - Other Considerations for Pregnancy and Breast Cancer
LactationSuppression of lactation does not improve prognosis. If surgery is planned, however, lactation should be suppressed to decrease the size and vascularity of the breasts. If chemotherapy is to be given, lactation should also be suppressed because many antineoplastics (i.e., cyclophosphamide and methotrexate), when given systemically, may occur in high levels in breast milk and would affect the nursing baby. In general, women receiving chemotherapy should not breastfeed.Fetal Consequences of Maternal Breast CancerNo damaging effects on the fetus from maternal breast cancer have been demonstrated, and there are no reported cases of maternal-fetal transfer of breast cancer cells. Consequences of Pregnancy in Patients with a History of Breast CancerBased on limited retrospective data, pregnancy does not appear to compromise the survival of women with a previous history of breast cancer, and no deleterious effects have been demonstrated in the fetus.[1,2,3,4,5,6,7,8,9] Some
Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Breast Cancer
Other PDQ summaries containing information related to breast cancer.
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Special Populations
Individuals With Little to Gain from ScreeningWomen with limited life expectancyAchieving balance between the benefits and harms of screening is especially important for women with a life expectancy of 5 years or less. Such women might have end-stage renal disease, severe dementia, terminal cancer, or severe comorbid disease with functional dependencies in activities of daily living. Early cancer detection and prompt treatment are unlikely to reduce morbidity or mortality within a woman's 5 years of expected survival, but the negative consequences of screening will occur immediately. Abnormal screening may trigger additional testing, with the attendant anxiety. In particular, the detection of a low-risk malignancy would probably result in a recommendation for treatment, which could impair rather than improve quality of life, without improving survival. Despite these considerations, many women with poor life expectancy due to age or health status often undergo screening